Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
MONDAY, April 11, 2022 (HealthDay News) — Regular users of phosphodiesterase type 5 inhibitors (PDE5Is) for erectile dysfunction may have an increased risk for adverse ocular events, according to a study published online April 7 in JAMA Ophthalmology.
Mahyar Etminan, Pharm.D., from the University of British Columbia in Vancouver, Canada, and colleagues quantified the risk for serous retinal detachment (SRD), retinal vascular occlusion (RVO), and ischemic optic neuropathy (ION) associated with the use of PDE5Is. The analysis included data from 213,033 men receiving PDE5Is (sildenafil, tadalafil, vardenafil, and avanafil) from 2006 through 2020, while the case-control analysis included a total of 1,146 cases of SRD (278), RVO (628), and ION (240) and 4,584 controls.
The researchers found that patients with SRD, RVO, and ION were more likely to have hypertension, diabetes, coronary artery disease, and sleep apnea. For the composite of any of the three outcomes, the incidence rate ratio (IRR) was 1.85 (incidence, 15.5 cases per 10,000 person-years). For the three individual outcomes, the adjusted IRR was 2.58 (incidence, 3.8 cases per 10,000 person-years) for SRD, 1.44 (incidence, 8.5 cases per 10,000 person-years) for RVO, and 2.02 (incidence, 3.2 cases per 10,000 person-years) for ION.
“Regular users of PDE5Is need to be cognizant of ocular adverse events associated with these drugs and alert their physicians if they experience any visual deficits,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Recurrent Visual Field Progression Happens for 1 in 4 With Glaucoma
Virtual Reality-Based Digital Defocus Vision Training May Aid Myopia in Children
Highly Aspherical Lenslets Effective for Reducing Myopia Progression in Children
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis
Adoption of Emergency General Surgery Verification Program Is Beneficial
Local Recurrence Rate Low After R0 Resection of Soft Tissue Sarcoma Tumors
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus
Implant, Patient Survival Do Not Differ for Robotic and Conventional Total Joint Replacement